Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel impenetrable—especially when they involve stem-cell secretomes, nanoparticle delivery science, and pages of trial data. Kala Pharmaceuticals SEC filings explained simply is exactly what most investors need when the latest 300-page document lands on EDGAR. Whether you are hunting for safety signals around KPI-012 or trying to gauge cash runway before the next Phase 2 read-out, our AI breaks down the jargon and highlights what really moves the share price.
Here you will find every form, from a Kala Pharmaceuticals annual report 10-K simplified to a Kala Pharmaceuticals quarterly earnings report 10-Q filing, plus Kala Pharmaceuticals 8-K material events explained within minutes of posting. Stock Titan’s AI-powered summaries show where milestone payments hit the income statement, flag trial-halt clauses hidden in footnotes, and answer real questions like “understanding Kala Pharmaceuticals SEC documents with AI” or “Kala Pharmaceuticals earnings report filing analysis” without scrolling line-by-line.
Need real-time visibility into management’s moves? Monitor Kala Pharmaceuticals insider trading Form 4 transactions and receive Kala Pharmaceuticals Form 4 insider transactions real-time alerts that spotlight option exercises and open-market buys. The page also connects each Kala Pharmaceuticals proxy statement executive compensation detail to dilution scenarios so you can calculate true cost of equity. Use our platform to track Kala Pharmaceuticals executive stock transactions Form 4, compare R&D trends across quarters, and export risk-factor lists for your model. Complex filings, clear insights—so you invest with confidence.
Kala Bio Chief Business Officer Darius Kharabi reported a sale of 4,511 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (ranging from $3.87 to $4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 16, 2021.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Kharabi maintains beneficial ownership of 62,566 shares, including 28,878 unvested RSUs
- The transaction was executed as a direct ownership sale
- The Form 4 was filed through an attorney-in-fact on June 26, 2025
This planned sale under Rule 10b5-1 demonstrates standard executive equity management for tax obligations rather than a discretionary trading decision.
Kala Bio CFO Mary Reumuth reported a sale of 3,631 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12). The transaction was executed under a pre-established 10b5-1 trading plan from November 9, 2020.
Key details of the transaction:
- The sale was specifically made to cover tax withholding obligations related to RSU vesting from a June 22, 2023 grant
- Following the transaction, Reumuth maintains beneficial ownership of 62,100 shares, including 28,906 unvested RSUs
- The transaction was reported via Form 4 within the required filing deadline
This planned sale under Rule 10b5-1 demonstrates standard executive equity management practices for tax obligations and does not indicate a significant change in the CFO's overall position in the company.
Kala Bio insider Todd Bazemore, serving as Interim CEO, President and COO, reported a transaction on June 24, 2025 involving the sale of 4,058 shares of common stock at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details of the transaction:
- Sale was executed under a 10b5-1 trading plan established on November 10, 2020
- Purpose: Cover tax withholding obligations related to RSU vesting from June 22, 2023 grant
- Post-transaction holdings: 83,699 shares (including 35,732 unvested RSUs) held directly
- Additional indirect ownership: 1 share held by son
The transaction was reported via Form 4 filing, signed by Mary Reumuth as attorney-in-fact on June 26, 2025, complying with SEC disclosure requirements for insider trading activity.
Kala Bio insider trading activity reported: Head of Research and Development and Chief Medical Officer Romulus K. Brazzell sold 5,251 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details:
- Sale executed under a 10b5-1 trading plan established November 9, 2020
- Transaction purpose: Cover tax withholding obligations from RSU vesting granted June 22, 2023
- Post-transaction holdings: 82,698 shares, including 35,952 unvested RSUs
- Transaction form: Direct ownership
The sale was made in compliance with SEC regulations and followed a pre-established trading plan, indicating a routine transaction rather than a strategic investment decision.
Kala Bio (NASDAQ:KALA) filed a routine Form 4 reporting that director Mark T. Iwicki sold 13,227 common shares on June 24 2025 at a weighted-average price of $4.01 per share, generating roughly $53 000 in gross proceeds.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9 2020 to cover tax-withholding obligations related to the vesting of restricted stock units (RSUs) granted on June 22 2023.
After the sale, Iwicki retains 258 433 shares, including 103 540 unvested RSUs, meaning the disposition represents slightly under 5 % of his prior beneficial ownership. No changes to company operations, strategy, or financial condition are disclosed.
Form 144 Notice of Proposed Sale filed for Kala Bio (NASDAQ: KALA) indicates an insider's intent to sell 5,251 shares of common stock with an aggregate market value of $21,056.51 through E*TRADE Financial Corporation. The planned sale is scheduled for June 24, 2025.
The securities being sold were originally acquired through a Restricted Stock Unit (RSU) vesting on June 24, 2025, where the insider received 16,450 shares as equity compensation. The total shares outstanding for Kala Bio are reported at 6,452,398.
Recent trading activity by the same seller through E*TRADE includes a previous sale of 3,687 shares on June 3, 2025, which generated gross proceeds of $13,789.38. This Form 144 filing represents the seller's declaration that they are not aware of any material adverse non-public information regarding the company.
KALA BIO, Inc. (KALA) – Form 144 Notice of Proposed Sale
An insider has filed to sell up to 4,511 common shares through E*TRADE on or after 24 June 2025. The filing lists an aggregate market value of $18,089, implying a reference price of roughly $4.01 per share. With 6,452,398 shares outstanding, the proposed sale represents approximately 0.07 % of total shares—an amount generally viewed as immaterial to public float and daily liquidity.
The seller’s position arises from the vesting of 12,281 restricted stock units on the same date. Over the past three months, the filer has already disposed of 730 shares for gross proceeds of $2,730. The Form 144 includes the customary certification that the filer is unaware of any undisclosed material information.
Because Form 144 is a routine notice rather than an executed sale, and given the small relative size, the disclosure is unlikely to have a meaningful impact on KALA’s share price or fundamental outlook.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
What is the core focus of Kala Pharmaceuticals Inc?
How does Kala Pharmaceuticals address unmet medical needs in eye diseases?
What conditions is Kala Pharmaceuticals targeting with its lead candidate?
What distinguishes Kala Pharmaceuticals' technology from traditional therapies?
How is the company positioned within the competitive biopharmaceutical landscape?
What role does clinical research play in Kala Pharmaceuticals' strategy?
How does Kala Pharmaceuticals fund its research and development initiatives?
What effects does the MSC-S platform aim to achieve?
